TY - JOUR
T1 - PrEP for key populations
T2 - results from the first PrEP demonstration project in the Democratic Republic of the Congo
AU - Franks, Julie
AU - Teasdale, Chloe
AU - Olsen, Halli
AU - Wang, Chunhui
AU - Mushimebele, Nadine
AU - Tenda Mazala, Richted
AU - Tchissambou, Tania
AU - Malele Bazola, Faustin
AU - Bingham, Trista
AU - Djomand, Gaston
AU - Mukinda, Elie
AU - Ewetola, Raimi
AU - Abrams, Elaine
AU - Reidy, William
N1 - Publisher Copyright:
© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Oral pre-exposure prophylaxis (PrEP) is recommended for persons at substantial risk for HIV, including female sex workers (FSW), men who have sex with men (MSM), people who inject drugs (PWID), and transgender women (TGW). We report on a PrEP demonstration project at seven clinics in the Democratic Republic of the Congo. Routinely collected data were abstracted to assess PrEP uptake, scheduled visit attendance, and self-reported adherence. Between February and May 2018, 469 eligible clients were offered daily oral PrEP; 75.1% accepted: 78.7% FSW, 20.5% MSM, and 0.9% TGW. Two percent also identified as PWID. Attendance was 64.5% at one-month visits; 82.1% at three-month visits; and among 47.7% of clients who initiated PrEP at least six months before data abstraction, 85.8% at six-month visits. Among 66.3% of clients with at least one adherence assessment, 39% self-reported low adherence. Results demonstrate the acceptability of PrEP delivered in healthcare settings serving FSW, MSM, PWID, and TGW.
AB - Oral pre-exposure prophylaxis (PrEP) is recommended for persons at substantial risk for HIV, including female sex workers (FSW), men who have sex with men (MSM), people who inject drugs (PWID), and transgender women (TGW). We report on a PrEP demonstration project at seven clinics in the Democratic Republic of the Congo. Routinely collected data were abstracted to assess PrEP uptake, scheduled visit attendance, and self-reported adherence. Between February and May 2018, 469 eligible clients were offered daily oral PrEP; 75.1% accepted: 78.7% FSW, 20.5% MSM, and 0.9% TGW. Two percent also identified as PWID. Attendance was 64.5% at one-month visits; 82.1% at three-month visits; and among 47.7% of clients who initiated PrEP at least six months before data abstraction, 85.8% at six-month visits. Among 66.3% of clients with at least one adherence assessment, 39% self-reported low adherence. Results demonstrate the acceptability of PrEP delivered in healthcare settings serving FSW, MSM, PWID, and TGW.
UR - http://www.scopus.com/inward/record.url?scp=85114650637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85114650637&partnerID=8YFLogxK
U2 - 10.1080/09540121.2021.1969332
DO - 10.1080/09540121.2021.1969332
M3 - Article
C2 - 34495772
AN - SCOPUS:85114650637
SN - 0954-0121
VL - 34
SP - 359
EP - 362
JO - AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV
JF - AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV
IS - 3
ER -
